Erythropoietin Drugs Market By Drug Type (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa), By Application Type (Anemia, Kidney Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

Erythropoietin is a growth regulating hormone that stimulates the production of red blood cells. Red blood cells are produced in bone marrow and help in carrying oxygen throughout the body. Erythropoietin drugs are used to treat anemia caused due to chronic kidney diseases, cancer treatment or HIV. There are different types of erythropoietin drugs available in market such as Procrit, Epogen and Aranesp. Epogen is the first blockbuster biologic for anemia by Amegen approved by the FDA and is widely used. Rising prevalence of renal diseases, cancer and HIV is the major driving factor of erythropoietin drugs market.

The report titled “Erythropoietin Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall erythropoietin drugs market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of drug, application and different geographies. The product types studied for analyzing the overall global erythropoietin drugs market are majorly segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa and others. The global erythropoietin drugs market is segmented by application type into cancer, hematology, renal diseases and neurology.

Geographically, the global erythropoietin drugs market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
  • Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year. Further cross-sectional presented in terms of drug type, applications and constituent region/country level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global erythropoietin drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global erythropoietin drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global erythropoietin drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffman-La Roche Ltd., Hospira, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and others.

Erythropoietin Drugs Market

Based on the type of application, the global erythropoietin drugs market is segmented as follows:


  • Anemia (Cancer and HIV)
    • Cancer
    • HIV
  • Kidney Disorders
  • Others

Currently, kidney disorders occupy a large share of the global erythropoietin drugs application market, due to rising incidence of renal diseases. Amgen’s blockbuster drug Epogen was the first approved by FDA for treatment of anemia arising due to chronic kidney diseases. Therefore, being the first in the market and high adoption rate led to dominance of kidney disorders in the market. Anemia occurring due to cancer and HIV is the fastest growing segment of erythropoietin drugs market. Rising prevalence of cancer and corresponding high usage of chemotherapy treatment that causes reduction in the count of RBCs is commonly observed phenomenon that fuels the demand of global erythropoietin drugs market.

Erythropoietin Drugs Market

Based on the type of drug, the global erythropoietin drugs market is segmented as follows:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin alfa
  • Others

Epoetin-alfa occupies the largest revenue share and dominates the global erythropoietin drugs market. Amgen’s Epogen (Epoetin–alfa) was the first billion dollar product of biotech industry that is widely used by physicians. It is the first biologic drug approved for treatment of anemia occurring due to cancer, HIV and chronic kidney disease. Epoetin-beta, a recombinant of Epo-alpha, also occupies significant share, due to better efficacy than alpha. Darbepoetin alfa is anticipated to be the fastest growing segment in the forecast period 2017-2025. It is also an Amgen product branded as Aranesp, a higher version of Epogen, with minimum side effect and high potency. With patent expiration, the biologics segment will decline, paving way to biosimilars in the market.

Erythropoietin Drugs Market

For the purpose of this study, the global erythropoietin drugs market is geographically categorized into:

  • North America (U.S., Canada)
  • Europe (U.K., Germany and Rest of Europe)
  • Asia Pacific (China, Japan and Rest of Asia)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East and Africa (UAE, Saudi Arabia, South Africa and Rest of Middle East and Africa)

Erythropoietin Drugs Market

In 2016, North America dominates the erythropoietin drugs market followed by Europe. Rising prevalence of chronic kidney diseases, cancer and HIV is the key reason for growth observed in erythropoietin drugs market in this region. According to the National Chronic Kidney Diseases fact sheet, around 15% of US adult suffer from CKD. Around 1.1 million people in U.S. are living with HIV, which bear a huge burden of mortality and morbidity. Well established healthcare infrastructure, and favorable reimbursement policies for chronic diseases, extensive research and development for novel drugs are some of the major factors that further fuels the growth of erythropoietin drugs market in North America. Most of the key players are based out of this region and are strategically expanding and strengthening distribution network thus raising their revenue share. Asia Pacific is anticipated to be the fastest growing market in the forecast period 2017-2025. Asia Pacific is base to huge population pool that is perpetually growing, thus there is a corresponding increase in incidence of chronic diseases that would further lead to demand for low cost drugs. Hence, Asia Pacific would be the most lucrative market for upcoming biosimilars producing companies. Further with improving healthcare infrastructure, government funding would drive the erythropoietin drugs market.

Choose License Type
Related Report

Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58548
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Connect With Us
24/7 Research Support